Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ALNA

Allena Pharmaceuticals (ALNA) Stock Price, News & Analysis

Allena Pharmaceuticals logo

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Key Stats

Today's Range
N/A
50-Day Range
$0.02
$0.16
52-Week Range
N/A
Volume
96,558 shs
Average Volume
15.69 million shs
Market Capitalization
$37,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNA Stock News Headlines

Allena Pharmaceuticals Inc ALNAQ Stock Quote
Allena Pharmaceuticals Inc (ALNAQ)
2025: Digital Asset Insights You Need to Know
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
San Francisco Pharmaceuticals News
ALNA.O
See More Headlines

ALNA Stock Analysis - Frequently Asked Questions

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) issued its earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06.

Allena Pharmaceuticals (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allena Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Zomedica (ZOM).

Company Calendar

Last Earnings
3/31/2022
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALNA
Employees
35
Year Founded
N/A

Profitability

Net Income
$-48,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.23 per share

Miscellaneous

Free Float
117,566,000
Market Cap
$37,000.00
Optionable
Not Optionable
Beta
1.13
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:ALNA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners